RxDoctor Payments Data

Joseph Nassir, MD

Internal Medicine · Huntington Beach, CANPI 1255301024

Payments from drug & device makers

$11,681in general payments, 2019–2025

Across 584 payments — averaging $20.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Amgen$876
  • Lilly USA, LLC$710
  • Amarin Pharma, Inc.$538
  • Pfizer$460
  • plus $5K from 52 others

What the payments were for

  • Food & beverage$11,44598%
  • Education$1251%
  • Gifts$1101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)95$1,904
AstraZeneca83$1,829
Amgen(2 entities)43$876
Lilly USA, LLC34$710
Amarin Pharma, Inc.38$538
Pfizer21$460
Novartis16$448
Novo Nordisk31$442
Johnson & Johnson19$372
Boehringer Ingelheim14$328
Kowa Pharmaceuticals America, Inc.16$324
Otsuka America Pharmaceutical, Inc.11$299
Lundbeck LLC14$243
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)16$239
Sanofi-aventis U.S. LLC13$216
GSK8$197
Sumitomo Pharma America, Inc.10$189
CMP Pharma, Inc.6$163
Scilex Pharmaceuticals Inc.8$153
Phathom Pharmaceuticals, Inc.3$117
Orasure Technologies Inc.2$110
Astellas Pharma US Inc6$104
Exact Sciences3$82
Paratek Pharmaceuticals, Inc.5$82
Teva Pharmaceuticals USA, Inc.4$76
Eisai Inc.3$72
Sunovion Pharmaceuticals Inc.5$71
Acella Pharmaceuticals, LLC4$64
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$64
Merck4$63
Genentech USA, Inc.3$59
Gilead2$55
Abbott2$48
Shield Therapeutics Inc2$47
Idorsia Pharmaceuticals US Inc2$44
Urovant Sciences Inc2$43
Hikma Pharmaceuticals USA2$42
Clarus Therapeutics Inc.2$41
Acerus Pharmaceuticals Corporation2$38
Sun Pharmaceutical Industries Inc.2$36
Alfasigma USA, Inc.2$35
Endo Pharmaceuticals Inc.2$35
Corcept Therapeutics1$33
Takeda Pharmaceuticals U.S.A., Inc.4$25
X4 Pharmaceuticals, Inc.1$24
Aytu Biopharma, Inc.2$23
Optinose US, Inc.1$23
Radius Health, Inc.1$22
Vertex1$21
Xeris Pharmaceuticals, Inc.1$21
Acadia Pharmaceuticals Inc1$20
Tolmar, Inc.1$19
Verrica Pharmaceuticals Inc.1$19
E.r. Squibb & Sons, L.L.C.1$18
Bayer1$15
Cequr Corporation1$14
Medicure Pharma Inc.1$12
Currax Pharmaceuticals LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,681 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$979,624
Medicare patients
599
Services billed
10,746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban215$113,814
JardianceEmpagliflozin104$88,986
OzempicSemaglutide75$86,818
Metformin Er GastricMetformin Hcl15$58,095
XareltoRivaroxaban75$54,599
JanuviaSitagliptin Phosphate58$51,879
FarxigaDapagliflozin Propanediol49$43,793
VascepaIcosapent Ethyl92$38,125
MounjaroTirzepatide24$35,444
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$30,446
ProliaDenosumab18$29,344
LinzessLinaclotide31$25,307
Breztri AerosphereBudesonide/Glycopyr/Formoterol38$24,189
MyrbetriqMirabegron48$23,914
Breo ElliptaFluticasone/Vilanterol55$23,745

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Combivent Respimat$328$126,923161 claims
PfizerEliquis$460$113,814215 claims
Novo NordiskOzempic$442$86,81875 claims
MerckJanuvia, Janumet, Janumet Xr$63$81,03989 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,829$67,98287 claims
Johnson & JohnsonXarelto$372$54,59975 claims
GSKTrelegy Ellipta, Breo Ellipta$197$54,192102 claims
AbbVieLinzess, Namzaric$1,904$46,29952 claims
Lilly USA, LLCMounjaro$710$35,44424 claims
AmgenProlia$876$29,34418 claims
Astellas Pharma US IncMyrbetriq$104$23,91448 claims
NovartisEntresto$448$8,82718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Huntington Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →